Kymera jumps after phase Ib study data show KT-621 delivers strong STAT6 degradation and broad clinical activity in patients with atopic dermatitis.

Shares of US clinical-stage biotech Kymera Therapeutic leapt almost 33% to $88.48 pre-market, as it announced compelling early results for its first-in-class oral STAT 6 degrade KT-621.

Group announced that it presented the latest results from a Phase Ib/II study of Lisaftoclax, a key investigational drug ...

Notre Dame's 2026 offense boasts playmakers and size, featuring a gap-closing class headlined by dual-threat QB Noah Grubbs.

Notre Dame has had one of the nation's top defenses for three seasons and strong recruiting was a big reason for that. The ...

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or ...